InsiderTrades

Form 4 for CAI Caris Life Sciences, Inc.

Accepted 2026-09-17 18:08:31 ET · period of report 2026-09-17 · accession 0002071959-26-000008 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-09-17 18:08 2026-09-17 CAI Brille Brian J See Remarks, Dir M - OptEx $2.44 +400.0K 630.3K +174% +$976.0K
D 2026-09-17 18:08 2026-09-17 CAI Brille Brian J See Remarks, Dir S - Sale+OE $30.33 -400.0K 230.3K -63% -$12.13M
D 2026-09-17 18:08 2026-09-17 CAI Brille Brian J See Remarks, Dir M - OptEx $0.00 -400.0K 1.60M -20% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-09-17 M A 400,000 $2.44 630,303 D — —
2 Common Common Stock 2026-09-17 S D 400,000 $30.33 230,303 D — — (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.2100 to $30.5650, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3 Derivative Stock Option 2026-09-17 M D 400,000 $0.00 1,600,000 D $2.44 · — to 2028-01-14 400,000 Common Stock (F4) The stock option is fully vested and exercisable.